RNA interference through non-coding microRNAs (miRNAs) represents a vital component of the innate antiviral immune response in plants and invertebrate animals; however, a role for cellular miRNAs in the defence against viral infection in mammalian organisms has thus far remained elusive 1 . Here we show that interferon beta (IFNb) rapidly modulates the expression of numerous cellular miRNAs, and that eight of these IFNb-induced miRNAs have sequence-predicted targets within the hepatitis C virus (HCV) genomic RNA. The introduction of synthetic miRNA-mimics corresponding to these IFNb-induced miRNAs reproduces the antiviral effects of IFNb on HCV replication and infection, whereas neutralization of these antiviral miRNAs with anti-miRNAs reduces the antiviral effects of IFNb against HCV. In addition, we demonstrate that IFNb treatment leads to a significant reduction in the expression of the liver-specific miR-122, an miRNA that has been previously shown to be essential for HCV replication 2 . Therefore, our findings strongly support the notion that mammalian organisms too, through the interferon system, use cellular miRNAs to combat viral infections.
miRNAs are a class of small non-coding RNA molecules that function through post-transcriptional regulation of gene expression by a process termed RNA interference (RNAi). Over 500 miRNAencoding genes, which seem to be exclusively transcribed by RNA polymerase II, have been identified in mammals. These primary microRNAs are processed by the enzymes Drosha/DGCR8/ RNASEN into hairpin-loop-containing pre-miRNAs, which are then subject to nuclear export via exportin 5. Further enzymatic processing of the pre-miRNAs by Dicer leads to a mature miRNA duplex that is loaded into the RNA-induced silencing complex (RISC), in which the miRNA guides RISC to complementary messenger RNAs. On the basis of the degree of homology between the miRNA and the mRNA, RISC can inhibit mRNA function by either promoting its cleavage or by inhibiting its translation 3, 4 . Particularly, the sequence complementarity in the 6-8 base pair 'seed region' at the 59 end of the miRNA-mRNA heteroduplex seems to determine the specificity of miRNA-targetRNA interactions 5 . RNAi-mediated targeting of viral RNAs was first recognized in plants as an antiviral defence mechanism, but it is now apparent that invertebrates also use RNAi to combat viral infection 1, 6, 7 . However, thus far, no evidence has been presented in support of a protective RNAi-based antiviral response in mammalian cells. Rather, the hypothesis has been proposed that ''the extremely potent interferon system has displaced RNAi as the key defence against virus infection in mammalian cells'' 1 . Indeed, several type I interferon (IFNa/b)-regulated gene products such as protein kinase R, the 2'-5' OA synthase/RNase L system, the adenosine deaminase ADAR1 or the Mx GTPases are important contributors to the antiviral properties of these cytokines 8, 9 . However, the possibility that IFNa/b might induce cellular miRNAs that target viral transcripts and thereby use RNAi as part of their arsenal against invading viruses has been left unexplored. To test whether IFNa/b could alter the expression of cellular miRNAs, we used microarray technology to analyse RNA derived from IFNa/b-or IFNc-stimulated cells. This initial screening effort identified ,30 miRNAs, the expression levels of which were increased or attenuated in response to IFNa/b or IFNc. Because we were interested in determining whether these miRNAs could potentially contribute to the antiviral effects of interferons, we performed sequence complementarity analysis of these miRNAs against viral transcripts or viral genomic RNAs with an initial focus on the crucial seed sequence. This approach revealed promising matches among several viruses, most of which harbour an RNA-based genome. Specifically, eight of the IFNb-induced miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296, miR-351, miR-431 and miR-448) displayed nearly perfect complementarity in their seed sequences with hepatitis C virus (HCV) RNA genomes. This finding was rather intriguing considering that IFNa and IFNb are the most common treatment regimen for HCV infection 10, 11 . Interestingly, a similar analysis of the hepatitis B virus (a DNA virus) yielded no significant matches.
HCV is the sole member of the hepacivirus genus of the Flaviviridiae family, and is represented by six major genotypes. The virion contains a 9.6 kb single-stranded RNA genome of positive polarity, with highly invariant 59 and 39 untranslated regions 12, 13 . After virus entry into the host cell, the viral genome is uncoated and serves as a template for the translation of a single polyprotein, which is subsequently processed by host and viral proteases. The nonstructural viral proteins then initiate the synthesis of a negativestrand RNA, which serves as a replication template for the generation of new positive-strand viral genomes 12, 13 . Sequence alignment of the six HCV genotypes illustrated that the putative miRNA target sites for the IFNb-induced miRNAs are located in areas strictly conserved among all HCV genotypes (see examples in Supplementary Fig. 1a ) as well as in regions that differ between the genotypes such that high seed-sequence complementarity occurs only with selected HCV genotypes (see examples in Supplementary Fig. 1b ).
To verify our microarray studies we analysed miRNA induction in response to IFNb in the human hepatoma cell line Huh7, as well as in freshly isolated primary murine hepatocytes by quantitative PCR (qPCR). As shown in Fig. 1a , b, IFNb treatment resulted in a similar induction of the prospective antiviral miRNAs in both cell types to that observed in ISG54, a well-characterized IFNa/b-regulated gene 14 . Two miRNAs (miR-125 and miR-142) that were found IFNb-unresponsive in the microarray analysis were included as negative controls. We next performed kinetic, as well as doseresponse, analyses of the induction of miRNAs by IFNb. Time course analysis revealed that induction of miR-1 and miR-196 occurs very rapidly, with peak concentrations within 30 min, and thus even precedes the upregulation of ISG54 (Fig. 1c) . In a similar manner to ISG54 induction, upregulation of miR-1 and miR-196 followed a classical dose-response curve between 1 and 1,000 U ml 21 IFNb (Fig. 1d) , and could be blocked by actinomycin D (data not shown), indicating that the increased levels of miRNAs are the result of transcriptional induction. miR-122 is specifically expressed in the liver, and previous studies using anti-miRNAs elegantly demonstrated that miR-122, and consequently Dicer 15 , are essential for HCV replication 2 . We therefore tested whether miR-122 was also subject to regulation by IFNb. As shown in Fig. 1e , IFNb-stimulation of Huh7 cells resulted in a transient, but pronounced (,80%) down-modulation of miR-122. In a similar manner to miRNA induction, 100 U ml 21 IFNb induced maximal attenuation of miR-122 expression, and no additional effect was observed with increased IFNb concentrations (Fig. 1e) .
To evaluate whether the eight IFNb-induced miRNAs with sequence matches in the HCV genome are indeed capable of inhibiting HCV replication, we transfected synthetic miRNA-mimics corresponding to these miRNAs into Huh-7 cells that harbour an autonomously replicating, dicistronic full-length HCV replicon 16, 17 . An anti-miRNA against miR-122 served as a positive control, because it had previously been shown to significantly reduce the abundance of replicon RNA in this system 2 . As expected, non-specific control miRNAs (individually or combined) or anti-miRNA oligos did not alter the amounts of HCV replicon RNA, whereas introduction of anti-miR-122 resulted in a ,70% reduction in viral RNA levels, as previously reported (Fig. 2a) . Transfection of the eight candidate miRNAs individually revealed that miRNAs miR-196, miR-296, miR-351, miR-431 and miR-448 were indeed able to substantially a, JFH1-replicon-containing Huh7 cells were transfected with single nonspecific miRNA-mimics (miR-ctrl), a pool of control miRNAs (miRctrl(mix5)) or anti-miRNAs (anti-miR-ctrl), or specific miRNA-mimics corresponding to the eight IFNb-induced miRNAs, or specific anti-miRNAs. In addition, a combination of the five miRNAs that displayed anti-viral activity individually was used (miR-mix5) with or without anti-miR-122, as indicated, and HCV RNA was quantified by qPCR after 48 h. b, Same as a, except Huh7 cells were infected with live JFH-1 virus for 48 h (error bars, means 6 s.d. of at least four independent experiments; P values are from paired Student's t-tests).
attenuate viral replication, whereas miRNAs miR-1, miR-30 and miR-128 were without effect (Fig. 2a) . Transfection of a mixture of the five functional miRNA-mimics yielded a .80% reduction in viral RNA load. As IFNb induces miRNAs miR-196, miR-296, miR-351, miR-431 and miR-448 but downregulates miR-122, we decided to imitate this cellular response by transfecting the mix of miRNAmimics in combination with anti-miR-122. Indeed, a small, but reproducible additive inhibitory effect on HCV replication was observed that was similar in efficacy to treatment of the cells with IFNb (Fig. 2a) . Virtually identical results were obtained when Huh7 cells were infected with live JFH1 HCV and either viral RNA levels (Fig. 2b) or viral foci formation ( Supplementary Fig. 2 ) were analysed, further corroborating the fact that the IFNb-induced alterations in the miRNA expression profile endow the cells with a pronounced antiviral state.
To investigate whether these anti-viral miRNAs are targeting the HCV genome rather than inducing a non-specific antiviral state through alteration of cellular gene expression, we took advantage of the fact that the J6CF HCV molecular clone has single-nucleotide variations in the predicted target seed sequences for miR-196 and miR-448 as opposed to JFH1 (Fig. 3a) . As J6CF is non-infectious in vitro, we employed an infection-competent J6CF/JFH1 chimaeric virus that carried the 'mutant' miR-448 and miR-196 target sites (chimaera J6/JFH) (Fig. 3a) . As anticipated, miR-196 was effective against JFH1, but not against J6/JFH, which contained the 'mutant' target site. Similarly, miR-448 only inhibited the replication of JFH1 containing the 'correct' target site, but was ineffective against J6/JFH (Fig. 3b) . Introduction of a compensatory single nucleotide change into miR-196 and miR-448 (designated miR-196* and miR-448*) to match their seed sequence to J6/JFH yielded a reversed efficacy profile compared to the wild-type miRNAs when they were tested against the two viruses. As such, both miR-196* and miR-448* were unable to subdue replication of JFH1, but clearly inhibited replication of J6/JFH (Fig. 3b) . Together, these results suggest that at least miR-196 and miR-448 are directly targeting the HCV genomic RNA.
Although the above described experiments demonstrate that IFNb-induced miRNAs, in conjunction with the downregulation of miR-122, are sufficient to induce an antiviral state, the question remained whether this modulation of cellular miRNA levels was necessary for IFNb to prevent HCV replication. To this end, we decided to counteract the IFNb-elicited changes in miRNA expression by transfecting anti-miRNAs against miRNAs miR-196, miR-296, miR-351, miR-431 and miR-448, with and without the inclusion of an miR-122 mimic. IFNb treatment leads to a .90% reduction in the amount of viral HCV replicon RNA and this inhibition is unaffected by transfected non-specific control anti-miRNAs. As shown in Fig. 4 , introduction of the anti-miRNA mix, or of the miR-122 mimic separately, attenuated the IFNb effect to ,75% inhibition. Co-transfection of the anti-miRNA mix and the miR-122 mimic further reduced the efficacy of IFNb to ,50%, indicating that In summary, our results demonstrate that IFNa/b upregulates several cellular miRNAs that are capable of inhibiting HCV replication and infection. In addition, downregulation of miR-122 in response to IFNb further contributes to the antiviral effects of this cytokine. These findings not only offer a new model of the host defence mechanisms that exist in mammalian cells, but also add a new component to the antiviral arsenal employed by interferons. Furthermore, although ample documentation is present in the literature for the developmentally regulated or tissue-specific expression of miRNAs and their dysregulation in malignant cells 18, 19 , little evidence existed for a direct and immediate transcriptional regulation of miRNAs by an endogenous ligand such as a cytokine or growth factor. Our results provide some of the first evidence for rapid changes in cellular miRNA levels in response to ligand stimulation. During the preparation of this manuscript, it was reported that IFNb induced upregulation of miR-155 (ref. 20) , a miRNA with, as of yet, no identified targets. The delayed induction kinetics observed in their studies supports the model that miR-155 upregulation is mediated by TNFa as part of an autocrine response elicited by IFNb, rather than by IFNb itself 20 . Nevertheless, this study and our present report provide the first examples of rapid modulation of cellular miRNAs as components of the mammalian innate immune response.
METHODS SUMMARY
Cell culture. The human hepatoma-derived cell lines Huh7 and their JFH-1-replicon-containing subclone were maintained in DMEM with 10% FCS/10mM Hepes, penicillin/streptomycin and 2 mM L-glutamine. The JFH-1 full-length genomic replicon construct pFGR-JFH-1 was obtained from T. Wakita 21 . A Huh7 cell clone that stably replicates the full-length genomic HCV RNA was selected and used in these experiments, as described previously 22 . The Huh7.5.1c2 cell line was derived from curing replicon-containing Huh-7.5.1 cells by interferon treatment. Primary murine hepatocytes (BalbC) were collected after collagenase perfusion of the livers for 30 min at 37 uC. miRNA array analysis. Microarray analysis of total RNA of interferonstimulated lymphocytes was performed at the Ohio State University Comprehensive Cancer Center Microarray Shared Resource, as described 23 .
RNA extraction. Total RNA was isolated using TriZol according to the manufacturer's instructions. Real-time PCR. Quantification of HCV genomic RNA was performed using HCV-and b-actin-or GAPDH-specific primers as described 16 . Real-time PCR-based quantification of miRNAs was performed using miRNA analysis kits specific for each individual miRNA (Applied Biosystems), according to the manufacturers instructions.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. HCV. JFH1-replicon-containing Huh7 cells were transfected with nonspecific miRNA-mimics (miR-ctrl), or non-specific anti-miRNAs (anti-miRctrl), or a pool of anti-miRNAs (anti-miR-ctrl (5)), or a combination of antimiRNA complementary to the five IFNb-induced miRNAs and with potent anti-viral effect (anti-miRNA-mix5), and/or with specific miRNAs and antimiRNAs, as indicated, before stimulation with IFNb for 48 h. HCV RNA was quantified by qPCR (means 6 s.d. of at least four independent experiments; P values are from paired Student's t-tests).
